Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Medical Management Following Excisional Surgery for Endometriosis
NCT06439524Phase 3Recruiting
- Sponsor
- Main Line Health
- Start
- Aug 2024
- Primary completion
- Jun 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator in endometriosis (2 arms), sponsored by Main Line Health. Primary endpoint: Endometriosis Health Profile 30 Score at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT06439524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439524.